Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 GLOBOCAN (2012). http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp.
  Google Scholar
• 2 De Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 62(4), 1190–1200 (2015).
  Medline CASGoogle Scholar
• 3 Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 313(22), 2263–2273 (2015).
  Medline CASGoogle Scholar
• 4 Yang ZF, Poon RT. Vascular changes in hepatocellular carcinoma. Anat. Rec. (Hoboken) 291(6), 721–734 (2008).
  Medline CASGoogle Scholar
• 5 Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27(2), 407–414 (1998).
  Medline CASGoogle Scholar
• 6 Mizukoshi E, Yamashita T, Arai K et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 57(4), 1448–1457 (2013).
  Medline CASGoogle Scholar
• 7 Flecken T, Schmidt N, Hild S et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8⁺ T-cell responses in hepatocellular carcinoma. Hepatology 59(4), 1415–1426 (2014).
  Medline CASGoogle Scholar
• 8 Nebbia G, Peppa D, Schurich A et al. Upregulation of the TIM-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS ONE 7(10), e47648 (2012).
  Medline CASGoogle Scholar
• 9 Li H, Wu K, Tao K et al. TIM-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56(4), 1342–1351 (2012).
  Medline CASGoogle Scholar
• 10 Bamboat ZM, Stableford JA, Plitas G et al. Human liver dendritic cells promote T cell hyporesponsiveness. J. Immunol. 182(4), 1901–1911 (2009).
  Medline CASGoogle Scholar
• 11 Chen KJ, Lin SZ, Zhou L et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS ONE 6(9), e24671 (2011).
  Medline CASGoogle Scholar
• 12 Ilkovitch D, Lopez DM. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res. 69(13), 5514–5521 (2009).
  Medline CASGoogle Scholar
• 13 Hoechst B, Voigtlaender T, Ormandy L et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50(3), 799–807 (2009).
  Medline CASGoogle Scholar
• 14 Liu Q, Zhang C, Sun A, Zheng Y, Wang L, Cao X. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J. Immunol. 182(10), 6207–6216 (2009).
  Medline CASGoogle Scholar
• 15 Han Y, Chen Z, Yang Y et al. Human CD14⁺ CTLA-4⁺ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology 59(2), 567–579 (2014).
  Medline CASGoogle Scholar
• 16 Ahlenstiel G, Titerence RH, Koh C et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 138(1), 325–335 e321–e322 (2010).
  Medline CASGoogle Scholar
• 17 Peppa D, Micco L, Javaid A et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 6(12), e1001227 (2010).
  Medline CASGoogle Scholar
• 18 Ju Y, Hou N, Meng J et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) mediates natural killer cell suppression in chronic hepatitis B. J. Hepatol. 52(3), 322–329 (2010).
  Medline CASGoogle Scholar
• 19 Cao D, Xu H, Guo G et al. Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. Inflammation 36(1), 110–120 (2013).
  Medline CASGoogle Scholar
• 20 Wu Y, Kuang DM, Pan WD et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology 57(3), 1107–1116 (2013).
  Medline CASGoogle Scholar
• 21 Cai L, Zhang Z, Zhou L et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin. Immunol. 129(3), 428–437 (2008).
  Medline CASGoogle Scholar
• 22 Kroy DC, Ciuffreda D, Cooperrider JH et al. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 146(2), 550–561 (2014).
  MedlineGoogle Scholar
• 23 Owusu Sekyere S, Suneetha PV, Kraft AR et al. A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. J. Hepatol. 62(1), 31–40 (2015).
  Medline CASGoogle Scholar
• 24 Kao C, Oestreich KJ, Paley MA et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 12(7), 663–671 (2011).
  Medline CASGoogle Scholar
• 25 Penna A, Pilli M, Zerbini A et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45(3), 588–601 (2007).
  Medline CASGoogle Scholar
• 26 Barathan M, Gopal K, Mohamed R et al. Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes. Apoptosis 20(4), 466–480 (2015).
  Medline CASGoogle Scholar
• 27 Gehring AJ, Ho ZZ, Tan AT et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137(2), 682–690 (2009).
  Medline CASGoogle Scholar
• 28 Behboudi S, Pereira SP. Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. World J. Hepatol. 2(7), 256–260 (2010).
  MedlineGoogle Scholar
• 29 Witkowski M, Spangenberg HC, Neumann-Haefelin C et al. Lack of ex vivo peripheral and intrahepatic alpha-fetoprotein-specific CD4⁺ responses in hepatocellular carcinoma. Int. J. Cancer 129(9), 2171–2182 (2011).
  Medline CASGoogle Scholar
• 30 Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206(13), 3015–3029 (2009).
  Medline CASGoogle Scholar
• 31 Wei F, Zhong S, Ma Z et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc. Natl Acad. Sci. USA 110(27), E2480–E2489 (2013).
  Medline CASGoogle Scholar
• 32 Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8(6), 467–477 (2008).
  Medline CASGoogle Scholar
• 33 Willimsky G, Schmidt K, Loddenkemper C, Gellermann J, Blankenstein T. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J. Clin. Invest. 123(3), 1032–1043 (2013).
  Medline CASGoogle Scholar
• 34 Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 46(1), 28–36 (2015).
  Medline CASGoogle Scholar
• 35 Shi F, Shi M, Zeng Z et al. PD-1 and PD-L1 upregulation promotes CD8(⁺) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer 128(4), 887–896 (2011).
  Medline CASGoogle Scholar
• 36 Zeng Z, Shi F, Zhou L et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS ONE 6(9), e23621 (2011).
  Medline CASGoogle Scholar
• 37 El-Khoueiry AB, Melero I, Crocenzi TS et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209–040. J. Clin. Oncol. 33(Suppl.) Abstract LBA101 (2015).
  MedlineGoogle Scholar
• 38 A study of nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. https://clinicaltrials.gov/ct2/show/NCT02576509?term=hepatocellular+carcinoma+nivolumab&rank=3.
  Google Scholar
• 39 Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206(8), 1717–1725 (2009).
  Medline CASGoogle Scholar
• 40 Chen Z, Shen S, Peng B, Tao J. Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model. Int. J. Hyperthermia 25(5), 374–382 (2009).
  Medline CASGoogle Scholar
• 41 Sangro B, Gomez-Martin C, De La Mata M et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59(1), 81–88 (2013).
  Medline CASGoogle Scholar
• 42 A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 in combination with Trans-Arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), Stereotactic Body Radiation Therapy (SBRT) or Cryoablation in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC). http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2013-C-0120.html.
  Google Scholar
• 43 Rong YH, Wan ZH, Song H et al. TIM-3 expression on peripheral monocytes and CD3+CD16/CD56+natural killer-like T cells in patients with chronic hepatitis B. Tissue Antigens 83(2), 76–81 (2014).
  Medline CASGoogle Scholar
• 44 Dolina JS, Braciale TJ, Hahn YS. Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology 59(4), 1351–1365 (2014).
  Medline CASGoogle Scholar
• 45 Moorman JP, Wang JM, Zhang Y et al. TIM-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection. J. Immunol. 189(2), 755–766 (2012).
  Medline CASGoogle Scholar
• 46 Yan W, Liu X, Ma H et al. TIM-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages. Gut 64(10), 1593–1604 (2015).
  Medline CASGoogle Scholar
• 47 Woo SR, Turnis ME, Goldberg MV et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72(4), 917–927 (2012).
  Medline CASGoogle Scholar
• 48 Chen N, Liu Y, Guo Y, Chen Y, Liu X, Liu M. LAG-3 negatively regulates the function of intrahepatic HCV-specific CD8 T cells. J. Gastroenterol. Hepatol. 30(12), 1788–1795 (2015).
  Medline CASGoogle Scholar
• 49 Safety study of anti-LAG-3 with and without anti-PD-1 in the treatment of solid tumors. https://clinicaltrials.gov/ct2/show/NCT01968109.
  Google Scholar
• 50 Johncilla M, Misdraji J, Pratt DS et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am. J. Surg. Pathol. 39(8), 1075–1084 (2015).
  MedlineGoogle Scholar
• 51 Cheng R, Cooper A, Kench J et al. Ipilimumab-induced toxicities and the gastroenterologist. J. Gastroenterol. Hepatol. 30(4), 657–666 (2015).
  Medline CASGoogle Scholar
• 52 Ravi S, Spencer K, Ruisi M et al. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J. Immunother. Cancer 2(1), 33 (2014).
  MedlineGoogle Scholar
• 53 Gardiner D, Lalezari J, Lawitz E et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS ONE 8(5), e63818 (2013).
  MedlineGoogle Scholar
• 54 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
  Medline CASGoogle Scholar
• 55 Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 8(5), 292–301 (2011).
  Medline CASGoogle Scholar
• 56 Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. Modulation of immunity by antiangiogenic molecules in cancer. Clin. Dev. Immunol. 2012, 492920 (2012).
  MedlineGoogle Scholar
• 57 Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep. 11(4), 577–591 (2015).
  Medline CASGoogle Scholar
• 58 Alfaro C, Suarez N, Gonzalez A et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br. J. Cancer 100(7), 1111–1119 (2009).
  Medline CASGoogle Scholar
• 59 Dikov MM, Ohm JE, Ray N et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 174(1), 215–222 (2005).
  Medline CASGoogle Scholar
• 60 Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol. Immunother. 56(6), 761–770 (2007).
  Medline CASGoogle Scholar
• 61 Marti LC, Pavon L, Severino P, Sibov T, Guilhen D, Moreira-Filho CA. Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation. Mem. Inst. Oswaldo Cruz 109(1), 70–79 (2014).
  Medline CASGoogle Scholar
• 62 Agudo J, Ruzo A, Tung N et al. The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids. Nat. Immunol. 15(1), 54–62 (2014).
  Medline CASGoogle Scholar
• 63 Fricke I, Mirza N, Dupont J et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer. Res. 13(16), 4840–4848 (2007).
  Medline CASGoogle Scholar
• 64 Terme M, Pernot S, Marcheteau E et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73(2), 539–549 (2013).
  Medline CASGoogle Scholar
• 65 Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109(4), 1568–1573 (2007).
  Medline CASGoogle Scholar
• 66 Arihara F, Mizukoshi E, Kitahara M et al. Increase in CD14⁺HLA^-DR^-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol. Immunother. 62(8), 1421–1430 (2013).
  Medline CASGoogle Scholar
• 67 Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92(11), 4150–4166 (1998).•• This report provided evidence that VEGF may act as an immunosuppressive factor.
  Medline CASGoogle Scholar
• 68 Grunewald M, Avraham I, Dor Y et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124(1), 175–189 (2006).
  Medline CASGoogle Scholar
• 69 Ohm JE, Gabrilovich DI, Sempowski GD et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101(12), 4878–4886 (2003).
  Medline CASGoogle Scholar
• 70 Huang Y, Chen X, Dikov MM et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110(2), 624–631 (2007).
  Medline CASGoogle Scholar
• 71 Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J. Immunol. 172(7), 4618–4623 (2004).
  Medline CASGoogle Scholar
• 72 Noman MZ, Buart S, Van Pelt J et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J. Immunol. 182(6), 3510–3521 (2009).
  Medline CASGoogle Scholar
• 73 Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26(5), 605–622 (2014).
  Medline CASGoogle Scholar
• 74 Hamzah J, Jugold M, Kiessling F et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453(7193), 410–414 (2008).•• This report provided genetic evidence that the lack of maturation of tumor vasculature is a key factor in immune evasion in cancer.
  Medline CASGoogle Scholar
• 75 Motz GT, Santoro SP, Wang LP et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20(6), 607–615 (2014).
  Medline CASGoogle Scholar
• 76 Osada T, Chong G, Tansik R et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57(8), 1115–1124 (2008).
  Medline CASGoogle Scholar
• 77 Ozao-Choy J, Ma G, Kao J et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69(6), 2514–2522 (2009).
  Medline CASGoogle Scholar
• 78 Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69(6), 2506–2513 (2009).
  Medline CASGoogle Scholar
• 79 Cao M, Xu Y, Youn JI et al. Kinase inhibitor sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab. Invest. 91(4), 598–608 (2011).
  Medline CASGoogle Scholar
• 80 Kusmartsev S, Eruslanov E, Kubler H et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 181(1), 346–353 (2008).
  Medline CASGoogle Scholar
• 81 Chen ML, Yan BS, Lu WC et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int. J. Cancer 134(2), 319–331 (2014).
  MedlineGoogle Scholar
• 82 Manning EA, Ullman JG, Leatherman JM et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer. Res. 13(13), 3951–3959 (2007).
  Medline CASGoogle Scholar
• 83 Voron T, Colussi O, Marcheteau E et al. VEGF-A modulates expression of inhibitory checkpoints on CD8⁺ T cells in tumors. J. Exp. Med. 212(2), 139–148 (2015).
  Medline CASGoogle Scholar
• 84 Ohta A, Ohta A, Madasu M et al. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J. Immunol. 183(9), 5487–5493 (2009).
  Medline CASGoogle Scholar
• 85 Sun J, Zhang Y, Yang M et al. Hypoxia induces T-cell apoptosis by inhibiting chemokine C receptor 7 expression: the role of adenosine receptor A(2). Cell. Mol. Immunol. 7(1), 77–82 (2010).
  Medline CASGoogle Scholar
• 86 Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The development and immunosuppressive functions of CD4(⁺) CD25(⁺) FoxP3(⁺) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front. Immunol. 3, 190 (2012).
  Medline CASGoogle Scholar
• 87 Facciabene A, Peng X, Hagemann IS et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475(7355), 226–230 (2011).• This report provided evidence that tumor hypoxia mediates both angiogenesis and immunosuppression in cancer via secretion of CCL28 and Treg infiltration in tumors.
  Medline CASGoogle Scholar
• 88 Chen W, Konkel JE. TGF-beta and ‘adaptive’ Foxp3(⁺) regulatory T cells. J. Mol. Cell. Biol. 2(1), 30–36 (2010).
  Medline CASGoogle Scholar
• 89 Tripathi C, Tewari BN, Kanchan RK et al. Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines oncostatin M and eotaxin. Oncotarget 5(14), 5350–5368 (2014).
  MedlineGoogle Scholar
• 90 Noman MZ, Desantis G, Janji B et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211(5), 781–790 (2014).• This report showed that PD-L1 may be directly activated by hypoxia-inducible factor 1-alpha, and its blockade led to CTL activation.
  Medline CASGoogle Scholar
• 91 Huang Y, Yuan J, Righi E et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl Acad. Sci. USA 109(43), 17561–17566 (2012).•• This report showed the dose-dependent effect of VEGFR2 blockade on the immune microenvironment of tumors in mice, and its impact on vaccine immunotherapy.
  Medline CASGoogle Scholar
• 92 Johansson A, Hamzah J, Payne CJ, Ganss R. Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc. Natl Acad. Sci. USA 109(20), 7841–7846 (2012).
  Medline CASGoogle Scholar
• 93 Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70(15), 6171–6180 (2010).
  Medline CASGoogle Scholar
• 94 Yasuda S, Sho M, Yamato I et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin. Exp. Immunol. 172(3), 500–506 (2013).
  Medline CASGoogle Scholar
• 95 Chen Y, Huang Y, Reiberger T et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59(4), 1435–1447 (2014).
  Medline CASGoogle Scholar
• 96 Chen Y, Ramjiawan RR, Reiberger T et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 61(5), 1591–1602 (2015).•• This report showed that CXCR4 inhibition could reprogram the immune microenvironment and facilitate checkpoint blockade in the face of hypoxia after sorafenib treatment in HCC models in mice with liver fibrosis.
  Medline CASGoogle Scholar
• 97 Hodi FS, Lawrence D, Lezcano C et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2(7), 632–642 (2014).• This report showed the feasibility of anti-VEGF therapy and checkpoint blockade in cancer patients.
  Medline CASGoogle Scholar